August 3, 2016 / 1:48 PM / a year ago

BRIEF-Concordia International confirms strategic review is ongoing

Aug 3 (Reuters) - Concordia International Corp :

* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business

* Confirmed that its review of strategic alternatives is ongoing and provided an update on its business

* Concordia has no liquidity or debt issues

* There was one formulary change affecting two products in its North America portfolio

* CVS did not reimburse for nilandron at all in past three years and has reimbursed dutoprol twice in 2016

* Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business

* CVS Health confirmed that nilandron and dutoprol will be removed from CVS Health’s formulary

* Removal of treatments from cvs health’s formulary is immaterial to business Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below